 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...8687888990919293949596...100101» |
- |||||||||| Verzenio (abemaciclib) / Eli Lilly
New P3 trial, Metastases: MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) - May 5, 2016
P3, N=450, Not yet recruiting, Sponsor: Eli Lilly and Company
- | Ibrance (palbociclib) / Pfizer
Phase classification, Combination therapy, Metastases: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Apr 28, 2016
P1/2, N=58, Active, not recruiting, Sponsor: Pfizer
Phase classification: P2 --> P1/2
- ||| New trial, Real-world evidence, Real-world, Metastases: Treat ER+ight: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy (clinicaltrials.gov) - Apr 28, 2016
P=N/A, N=320, Recruiting, Sponsor: Novartis Pharmaceuticals
- letrozole / Generic mfg.
Trial primary completion date, IO biomarker: Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. (clinicaltrials.gov) - Apr 27, 2016
P=N/A, N=30, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Phase classification: P2 --> P1/2 Trial primary completion date: Jun 2016 --> Dec 2016
- Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
Enrollment closed: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Apr 22, 2016
P2, N=32, Active, not recruiting, Sponsor: Midwestern Regional Medical Center
Trial primary completion date: Jun 2016 --> Dec 2016 Not yet recruiting --> Active, not recruiting
- |||||| Ibrance (palbociclib) / Pfizer
Enrollment open, Combination therapy, Metastases: Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate (clinicaltrials.gov) - Apr 21, 2016
P3, N=130, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- letrozole / Generic mfg.
Trial withdrawal: Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Apr 20, 2016
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Terminated --> Withdrawn
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date: Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=150, Active, not recruiting, Sponsor: Mayo Clinic
Terminated --> Withdrawn Trial primary completion date: Sep 2015 --> Sep 2016
- |||| Enrollment open, Trial initiation date, PARP Biomarker: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (clinicaltrials.gov) - Apr 19, 2016
P2, N=200, Recruiting, Sponsor: Haukeland University Hospital
Trial primary completion date: Sep 2015 --> Sep 2016 Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Apr 2016
- Merional (menotropin) / IBSA Institute Biochemical SA, Choriomon (human choriomon gonadotropin (hCG)) / IBSA Institute Biochemical SA
New P4 trial: AIPRICSI: Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI (clinicaltrials.gov) - Apr 18, 2016
P4, N=20, Not yet recruiting, Sponsor: Minia University
- letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Apr 18, 2016
P2, N=40, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- || letrozole / Generic mfg.
New P3 trial: Dual FSH/HCG Trigger in Letrozole Stimulated Intrauterine Insemination Cycles in Women With Unexplained Infertility (clinicaltrials.gov) - Apr 15, 2016
P3, N=108, Completed, Sponsor: Benha University
- || Piqray (alpelisib) / Novartis
Trial primary completion date, Metastases: BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 11, 2016
P1, N=56, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Apr 2016 Trial primary completion date: May 2016 --> May 2017
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. (clinicaltrials.gov) - Apr 11, 2016
P3, N=140, Completed, Sponsor: Cairo University
Trial primary completion date: May 2016 --> May 2017 Recruiting --> Completed | Initiation date: Nov 2014 --> May 2013 | Trial primary completion date: May 2016 --> Jan 2015
- || samotolisib (LY3023414) / Eli Lilly
Trial primary completion date, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 7, 2016
P1, N=130, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Completed | Initiation date: Nov 2014 --> May 2013 | Trial primary completion date: May 2016 --> Jan 2015 Trial primary completion date: Sep 2016 --> Jul 2017
- |||| Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Enrollment open, Metastases: CHEOPS: Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. (clinicaltrials.gov) - Apr 6, 2016
P2, N=130, Recruiting, Sponsor: ARCAGY/ GINECO GROUP
Trial primary completion date: Sep 2016 --> Jul 2017 Not yet recruiting --> Recruiting
- |||||| Ibrance (palbociclib) / Pfizer
Enrollment open, Combination therapy, Metastases: Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Apr 6, 2016
P3, N=150, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
New P3 trial, Combination therapy, Metastases: VICTORIANE: A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease (clinicaltrials.gov) - Apr 6, 2016
P3, N=340, Recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
- | Ibrance (palbociclib) / Pfizer
New P2 trial, Combination therapy, Metastases: PALEO: Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer (clinicaltrials.gov) - Apr 6, 2016
P2, N=80, Not yet recruiting, Sponsor: Nordic Society for Gynaecologic Oncology
- letrozole / Generic mfg., everolimus / Generic mfg.
Trial suspension: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Apr 4, 2016
P2, N=20, Suspended, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Active, not recruiting --> Suspended
- || letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Apr 1, 2016
P2, N=202, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Suspended Trial primary completion date: Dec 2016 --> Jun 2016
- | everolimus / Generic mfg.
Enrollment change: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Mar 24, 2016
P2, N=38, Recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2016 --> Jun 2016 N=70 --> 38
- | Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment closed, Enrollment change, Metastases: Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone (clinicaltrials.gov) - Mar 21, 2016
P2, N=44, Active, not recruiting, Sponsor: Translational Research in Oncology
N=70 --> 38 Recruiting --> Active, not recruiting | N=150 --> 44
- | everolimus / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Mar 21, 2016
P2, N=48, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting | N=150 --> 44 Recruiting --> Active, not recruiting
- |||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial primary completion date: MA.17R: Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy (clinicaltrials.gov) - Mar 19, 2016
P3, N=1918, Active, not recruiting, Sponsor: Canadian Cancer Trials Group
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2017 --> Jul 2015
- ||||| Kisqali (ribociclib) / Novartis
New P2 trial: FELINE: Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer (clinicaltrials.gov) - Mar 18, 2016
P2, N=120, Recruiting, Sponsor: Qamar Khan
- Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 11, 2016
P2, N=56, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jul 2017 --> Jul 2015 Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Mar 2016 | Trial primary completion date: Dec 2018 --> Sep 2018
- letrozole / Generic mfg.
New P4 trial: Administration of Single High Dose Letrozole for Ovulation Induction (clinicaltrials.gov) - Mar 9, 2016
P4, N=36, Not yet recruiting, Sponsor: Mount Sinai Hospital, Canada
- || Trial primary completion date, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Mar 8, 2016
P2, N=317, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Mar 2016 | Trial primary completion date: Dec 2018 --> Sep 2018 Trial primary completion date: Jul 2016 --> Nov 2016
- Kisqali (ribociclib) / Novartis, buparlisib (AN2025) / Adlai Nortye
Trial primary completion date, Combination therapy, Metastases: LeeBLet: Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (clinicaltrials.gov) - Mar 8, 2016
P1, N=13, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2016 --> Nov 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- letrozole / Generic mfg.
New trial: BARONET: Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers (clinicaltrials.gov) - Mar 8, 2016
P=N/A, N=40, Not yet recruiting, Sponsor: NHS Tayside
- lapatinib / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment change, Trial termination, Combination therapy, Metastases: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer (clinicaltrials.gov) - Mar 5, 2016
P2, N=7, Terminated, Sponsor: University of Maryland
Trial primary completion date: Dec 2015 --> Jun 2016 N=76 --> 7 | Active, not recruiting --> Terminated; low accrual
- | letrozole / Generic mfg.
Trial completion, Metastases: Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer (clinicaltrials.gov) - Feb 27, 2016
P2, N=33, Completed, Sponsor: NCIC Clinical Trials Group
N=76 --> 7 | Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Completed
- Ibrance (palbociclib) / Pfizer
New P2/3 trial, Combination therapy, Metastases: PALINA: Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer (clinicaltrials.gov) - Feb 26, 2016
P2/3, N=35, Not yet recruiting, Sponsor: Georgetown University
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Feb 24, 2016
P1/2, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: May 2017 --> Sep 2017
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer (clinicaltrials.gov) - Feb 24, 2016
P2, N=75, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: May 2017 --> Sep 2017 Trial primary completion date: Dec 2014 --> Sep 2016
- Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
New P2 trial: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Feb 24, 2016
P2, N=32, Not yet recruiting, Sponsor: Midwestern Regional Medical Center
- | carotuximab IV (ENV-105) / Kairos Pharma
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (clinicaltrials.gov) - Feb 23, 2016
P1/2, N=35, Recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Dec 2014 --> Sep 2016 Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Feb 2016 | Trial primary completion date: Sep 2017 --> Feb 2018
- letrozole / Generic mfg.
Trial primary completion date: Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment (clinicaltrials.gov) - Feb 21, 2016
P2/3, N=50, Recruiting, Sponsor: Helsinki University Central Hospital
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Feb 2016 | Trial primary completion date: Sep 2017 --> Feb 2018 Trial primary completion date: Dec 2015 --> Apr 2017
- letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Feb 21, 2016
P2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Apr 2017 Trial primary completion date: Apr 2016 --> Apr 2017
- letrozole / Generic mfg.
New P3 trial: The Letrozole Administration During Luteal Phase (clinicaltrials.gov) - Feb 21, 2016
P3, N=50, Not yet recruiting, Sponsor: The Affiliated Hospital of Inner Mongolia Medical University
- ||| Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: BOOSTER: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Feb 17, 2016
P2, N=160, Active, not recruiting, Sponsor: Japan Breast Cancer Research Group
Trial primary completion date: Apr 2016 --> Apr 2017 Recruiting --> Active, not recruiting
- Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, Trial primary completion date: PREDIX LumB: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (clinicaltrials.gov) - Feb 17, 2016
P2, N=200, Recruiting, Sponsor: Thomas Hatschek
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Feb 2015 | Trial primary completion date: Dec 2017 --> Jun 2018
- | letrozole / Generic mfg.
Enrollment open, Enrollment change: PCOSAPct: The Clinical Trial of Acupuncture Pre-treatment on PCOS (clinicaltrials.gov) - Feb 17, 2016
P3, N=384, Recruiting, Sponsor: The First Affiliated Hospital of Guangzhou Medical University
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Feb 2015 | Trial primary completion date: Dec 2017 --> Jun 2018 Not yet recruiting --> Recruiting | N=240 --> 384
- ||| gedatolisib (PF-05212384) / Celcuity
New P1 trial, Combination therapy, Metastases: B2151009: A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer (clinicaltrials.gov) - Feb 17, 2016
P1, N=121, Not yet recruiting, Sponsor: Pfizer
- |||||||||| Ibrance (palbociclib) / Pfizer
New P3 trial, Combination therapy, Metastases: Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Feb 10, 2016
P3, N=150, Not yet recruiting, Sponsor: Pfizer
- | Mekinist (trametinib) / Novartis
Clinical: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov) - Feb 9, 2016
P2/3, N=250, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | N=240 --> 384 Suspended --> Recruiting
- |||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial primary completion date: NSABP B-42: Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer (clinicaltrials.gov) - Feb 8, 2016
P3, N=3966, Active, not recruiting, Sponsor: NSABP Foundation Inc
Suspended --> Recruiting Trial primary completion date: Oct 2015 --> Jan 2016
- Mekinist (trametinib) / Novartis
Clinical: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov) - Feb 8, 2016
P2/3, N=250, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2015 --> Jan 2016 Recruiting --> Suspended
- | Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Phase classification, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Feb 2, 2016
P1/2, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Suspended Phase classification: P1 --> P1/2